193 related articles for article (PubMed ID: 31651522)
1. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.
Yoshimoto M; Yamada Y; Ishihara S; Kohashi K; Toda Y; Ito Y; Yamamoto H; Furue M; Nakashima Y; Oda Y
Am J Surg Pathol; 2020 Jan; 44(1):87-97. PubMed ID: 31651522
[TBL] [Abstract][Full Text] [Related]
2. Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Lee AY; Agaram NP; Qin LX; Kuk D; Curtin C; Brennan MF; Singer S
Ann Surg Oncol; 2016 Mar; 23(3):818-25. PubMed ID: 26759307
[TBL] [Abstract][Full Text] [Related]
3. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems.
Huang HY; Lal P; Qin J; Brennan MF; Antonescu CR
Hum Pathol; 2004 May; 35(5):612-21. PubMed ID: 15138937
[TBL] [Abstract][Full Text] [Related]
4. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma.
Mentzel T; Brown LF; Dvorak HF; Kuhnen C; Stiller KJ; Katenkamp D; Fletcher CD
Virchows Arch; 2001 Jan; 438(1):13-22. PubMed ID: 11213831
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated mortality and prognostic factors in myxofibrosarcoma - A retrospective review of 109 patients.
Gilg MM; Sunitsch S; Leitner L; Bergovec M; Szkandera J; Leithner A; Liegl-Atzwanger B
Orthop Traumatol Surg Res; 2020 Oct; 106(6):1059-1065. PubMed ID: 32778437
[TBL] [Abstract][Full Text] [Related]
6. Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma.
Hu Q; Zhou S; Hu X; Zhang H; Huang S; Wang Y
J Cell Mol Med; 2020 Jan; 24(1):1010-1021. PubMed ID: 31742892
[TBL] [Abstract][Full Text] [Related]
7. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma.
Iwata S; Yonemoto T; Araki A; Ikebe D; Kamoda H; Hagiwara Y; Ishii T
J Surg Oncol; 2014 Nov; 110(6):707-11. PubMed ID: 24975462
[TBL] [Abstract][Full Text] [Related]
8. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
[TBL] [Abstract][Full Text] [Related]
9. Surgical margins do not affect prognosis in high grade myxofibrosarcoma.
Sambri A; Bianchi G; Righi A; Ferrari C; Donati D
Eur J Surg Oncol; 2016 Jul; 42(7):1042-8. PubMed ID: 27260849
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinical factors impacting recurrence in myxofibrosarcoma.
Chen W; Ye M; Sun Y; Wei Y; Huang Y
Sci Rep; 2024 Feb; 14(1):3903. PubMed ID: 38365844
[TBL] [Abstract][Full Text] [Related]
11. GLUT-1 expression is helpful to distinguish myxofibrosarcoma from nodular fasciitis.
Nakayama S; Nishio J; Aoki M; Koga K; Nabeshima K; Yamamoto T
Histol Histopathol; 2023 Jan; 38(1):47-51. PubMed ID: 35792526
[TBL] [Abstract][Full Text] [Related]
12. Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma.
Sun H; Liu J; Hu F; Xu M; Leng A; Jiang F; Chen K
Front Genet; 2023; 14():1109491. PubMed ID: 36873946
[TBL] [Abstract][Full Text] [Related]
13. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases.
Nascimento AF; Bertoni F; Fletcher CD
Am J Surg Pathol; 2007 Jan; 31(1):99-105. PubMed ID: 17197925
[TBL] [Abstract][Full Text] [Related]
14. [Low malignancy myxofibrosarcoma versus low malignancy fibromyxoid sarcoma. Distinct entities with similar names but different clinical course].
Mentzel T; Katenkamp D; Fletcher CD
Pathologe; 1996 Mar; 17(2):116-21. PubMed ID: 8650138
[TBL] [Abstract][Full Text] [Related]
15. Tail of Superficial Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma After Preoperative Radiotherapy.
Imanishi J; Slavin J; Pianta M; Jackett L; Ngan SY; Tanaka T; Charoenlap C; DI Bella C; Choong PF
Anticancer Res; 2016 May; 36(5):2339-44. PubMed ID: 27127141
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma.
Song B; Lee K; Lee C; Moon KC
Pathol Int; 2018 Sep; 68(9):509-516. PubMed ID: 30094896
[TBL] [Abstract][Full Text] [Related]
17. Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors.
Bekki H; Yamamoto H; Takizawa K; Iwasaki T; Otsuka H; Yamada Y; Kohashi K; Harimaya K; Iwamoto Y; Oda Y
Pathol Res Pract; 2017 Jun; 213(6):674-679. PubMed ID: 28476380
[TBL] [Abstract][Full Text] [Related]
18. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
19. Low-grade fibromyxoid sarcoma versus low-grade myxofibrosarcoma in the extremities and trunk. A comparison of clinicopathological and immunohistochemical features.
Oda Y; Takahira T; Kawaguchi K; Yamamoto H; Tamiya S; Matsuda S; Tanaka K; Iwamoto Y; Tsuneyoshi M
Histopathology; 2004 Jul; 45(1):29-38. PubMed ID: 15228441
[TBL] [Abstract][Full Text] [Related]
20. Does pre-operative MRI predict the risk of local recurrence in primary myxofibrosarcoma of the extremities?
Sambri A; Spinnato P; Bazzocchi A; Tuzzato GM; Donati D; Bianchi G
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e181-e186. PubMed ID: 31111597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
